CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis
BackgroundColorectal cancer (CRC) remains a predominant contributor to cancer-related mortality globally, with its resistance to immunotherapeutic strategies presenting a formidable challenge in patient management. Recent investigations have illuminated the prospective involvement of ferroptosis, a...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1589423/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850095005936386048 |
|---|---|
| author | Canyu Liu Qiujun Liu Yuanhao Lv Tingmin Chang Shiyi Song Yuang Ding Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Yanxuan Liu |
| author_facet | Canyu Liu Qiujun Liu Yuanhao Lv Tingmin Chang Shiyi Song Yuang Ding Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Yanxuan Liu |
| author_sort | Canyu Liu |
| collection | DOAJ |
| description | BackgroundColorectal cancer (CRC) remains a predominant contributor to cancer-related mortality globally, with its resistance to immunotherapeutic strategies presenting a formidable challenge in patient management. Recent investigations have illuminated the prospective involvement of ferroptosis, a regulated form of cell death, in both cancer progression and the development of resistance to therapeutic interventions.ObjectiveThis study aims to elucidate the prognostic significance of CPLX1 in CRC, specifically its correlation with immunotherapy resistance and its association with ferroptosis, thereby contributing to a deeper understanding of tumor biology and therapeutic vulnerability.MethodsWe conducted an integrative analysis of RNA-seq datasets from the TCGA-COAD and TCGA-READ projects, along with the GEO GSE156451 dataset, to discern differentially expressed genes. Expression levels of CPLX1 were evaluated utilizing the TIMER 2.0 database, and survival analyses were performed via Kaplan-Meier plots and Cox regression modeling to assess prognostic implications. Additionally, mutational analyses through cBioPortal and COSMIC datasets were employed to identify CPLX1 mutations in COAD. Co-expression and functional enrichment analyses, alongside Gene Set Enrichment Analysis (GSEA), were also conducted to delineate pathways impacted by CPLX1.ResultsOur findings indicate that high expression levels of CPLX1 are significantly correlated with poor prognostic outcomes in CRC patients. Through immune infiltration analyses employing ssGSEA, we observed notable associations between CPLX1 expression and specific immune cell populations. Furthermore, the interaction between CPLX1 and ferroptosis-related genes suggests a potential mechanistic linkage that could underpin therapeutic resistance.ConclusionCPLX1 is identified as a novel prognostic biomarker in CRC, exhibiting clear correlations with both immunotherapy resistance and ferroptosis. These findings indicate that targeting CPLX1 may provide novel therapeutic strategies to ameliorate treatment resistance in CRC. |
| format | Article |
| id | doaj-art-7573db957f744a2e95e9c88dc9e52847 |
| institution | DOAJ |
| issn | 1664-3224 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj-art-7573db957f744a2e95e9c88dc9e528472025-08-20T02:41:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-07-011610.3389/fimmu.2025.15894231589423CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosisCanyu Liu0Qiujun Liu1Yuanhao Lv2Tingmin Chang3Shiyi Song4Yuang Ding5Jiateng Zhong6Jiateng Zhong7Jiateng Zhong8Jiateng Zhong9Jiateng Zhong10Yanxuan Liu11Department of Digestive Endoscopy Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaDepartment of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaDepartment of Pathology, Xinxiang Medical University, Xinxiang, ChinaDepartment of Digestive Endoscopy Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaDepartment of Digestive Endoscopy Center, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaDepartment of Pathology, Xinxiang Medical University, Xinxiang, ChinaDepartment of Pathology, Xinxiang Medical University, Xinxiang, ChinaDepartment of Pathology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaXinxiang Key Laboratory of Precision Diagnosis and Treatment for Colorectal Cancer, Xinxiang First People’s Hospital, Xinxiang, ChinaXinxiang Engineering Technology Research Center of Digestive Tumor Molecular Diagnosis, Xinxiang Medical University, Xinxiang, ChinaHenan Province Engineering Technology Research Center of Tumor Diagnostic Biomarkers and RNA Interference Drugs, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaDepartment of Medical Genetics, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, ChinaBackgroundColorectal cancer (CRC) remains a predominant contributor to cancer-related mortality globally, with its resistance to immunotherapeutic strategies presenting a formidable challenge in patient management. Recent investigations have illuminated the prospective involvement of ferroptosis, a regulated form of cell death, in both cancer progression and the development of resistance to therapeutic interventions.ObjectiveThis study aims to elucidate the prognostic significance of CPLX1 in CRC, specifically its correlation with immunotherapy resistance and its association with ferroptosis, thereby contributing to a deeper understanding of tumor biology and therapeutic vulnerability.MethodsWe conducted an integrative analysis of RNA-seq datasets from the TCGA-COAD and TCGA-READ projects, along with the GEO GSE156451 dataset, to discern differentially expressed genes. Expression levels of CPLX1 were evaluated utilizing the TIMER 2.0 database, and survival analyses were performed via Kaplan-Meier plots and Cox regression modeling to assess prognostic implications. Additionally, mutational analyses through cBioPortal and COSMIC datasets were employed to identify CPLX1 mutations in COAD. Co-expression and functional enrichment analyses, alongside Gene Set Enrichment Analysis (GSEA), were also conducted to delineate pathways impacted by CPLX1.ResultsOur findings indicate that high expression levels of CPLX1 are significantly correlated with poor prognostic outcomes in CRC patients. Through immune infiltration analyses employing ssGSEA, we observed notable associations between CPLX1 expression and specific immune cell populations. Furthermore, the interaction between CPLX1 and ferroptosis-related genes suggests a potential mechanistic linkage that could underpin therapeutic resistance.ConclusionCPLX1 is identified as a novel prognostic biomarker in CRC, exhibiting clear correlations with both immunotherapy resistance and ferroptosis. These findings indicate that targeting CPLX1 may provide novel therapeutic strategies to ameliorate treatment resistance in CRC.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1589423/fullCPLX1biomarkerCRCtumor-immune infiltrationferroptosis |
| spellingShingle | Canyu Liu Qiujun Liu Yuanhao Lv Tingmin Chang Shiyi Song Yuang Ding Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Jiateng Zhong Yanxuan Liu CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis Frontiers in Immunology CPLX1 biomarker CRC tumor-immune infiltration ferroptosis |
| title | CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis |
| title_full | CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis |
| title_fullStr | CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis |
| title_full_unstemmed | CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis |
| title_short | CPLX1 is a novel prognostic biomarker in CRC correlating with immunotherapy resistance and ferroptosis |
| title_sort | cplx1 is a novel prognostic biomarker in crc correlating with immunotherapy resistance and ferroptosis |
| topic | CPLX1 biomarker CRC tumor-immune infiltration ferroptosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1589423/full |
| work_keys_str_mv | AT canyuliu cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT qiujunliu cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT yuanhaolv cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT tingminchang cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT shiyisong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT yuangding cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT jiatengzhong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT jiatengzhong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT jiatengzhong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT jiatengzhong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT jiatengzhong cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis AT yanxuanliu cplx1isanovelprognosticbiomarkerincrccorrelatingwithimmunotherapyresistanceandferroptosis |